Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atyr Pharma Inc (NQ: LIFE )

1.270 -0.030 (-2.31%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 187,696
Open 1.290
Bid (Size) 1.270 (19)
Ask (Size) 1.330 (1)
Prev. Close 1.300
Today's Range 1.220 - 1.320
52wk Range 1.080 - 2.619
Shares Outstanding 54,291,754
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Beat of Life Entertainment's 'Diya Jalao Roshni Lao' Campaign: Lighting Up Lives and Preserving Tradition!
The "Diya Jalao Roshni Lao" campaign was initiated by the Beat of Life Entertainment company in 2022. Its aim is to draw people's attention to our culture, the hard work of potters, hope, their lives,... 
Via IssueWire
Topics Religion
Exposures Religion
aTyr Pharma to Present at November Investor Conferences
From aTyr Pharma, Inc.
Via GlobeNewswire

Performance

YTD
-46.19%
-46.19%
1 Month
+3.25%
+3.25%
3 Month
-25.29%
-25.29%
6 Month
-42.53%
-42.53%
1 Year
-44.30%
-44.30%

More News

Read More
aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILD
From aTyr Pharma, Inc.
Via GlobeNewswire
Analyst Expectations for aTyr Pharma's Future
Via Benzinga
The Latest Analyst Ratings for aTyr Pharma
Via Benzinga
aTyr Pharma: Q1 Earnings Insights
Via Benzinga
Where aTyr Pharma Stands With Analysts
Via Benzinga
aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
From aTyr Pharma, Inc.
Via GlobeNewswire
$12M Bet On This Trucking Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
aTyr Pharma's Cash Runway Secured till 2026, Despite Lack of Material Catalysts: Oppenheimer Analyst
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 5, 2023
Via Benzinga
aTyr Pharma's Earnings: A Preview
Via Benzinga
7 Growth Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2023
Via InvestorPlace
3 Stocks and Cryptos With the Highest Potential Returns
Via InvestorPlace
7 Hot Growth Stocks Poised to Triple in 2023
Via InvestorPlace
Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
This Company Is Beginning A Pivotal Phase 3 EFZO-FIT™ Study. Could It Be A Much-Needed Treatment For Pulmonary Sarcoidosis?
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Beat Of Life Entertainment- A One Stop Solution For Internet Marketing
Via IssueWire
Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary
Via Benzinga
aTyr Pharma Gets FDA Fast Track Status For Systemic Sclerosis Candidate
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.